RXRX (Recursion Pharmaceuticals) Total Assets: $1,339.52 Mil (As of Mar. 2026)


RXRX Recursion Pharmaceuticals Inc RXRX
77 GF Score
Price $3.96
GF Value $4.14
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Recursion Pharmaceuticals Total Assets?

Recursion Pharmaceuticals RXRX 77 Total Assets is $1,339.52 Mil as of Mar. 2026. GuruFocus rates RXRX with a GF Score™ of 77/100 and a GF Value™ of $4.14 (Fairly Valued). The stock has 4 warning signs investors should review.

Recursion Pharmaceuticals's Total Assets for the quarter that ended in Mar. 2026 was $1,339.52 Mil.

Warning Sign:

If a company builds assets at 88.4% a year, faster than its revenue growth rate of 38.6% over the past 5 years, it means that the company may be getting less efficient.

During the past 12 months, Recursion Pharmaceuticals's average Total Assets Growth Rate was -14.90% per year. During the past 3 years, the average Total Assets Growth Rate was 69.00% per year. During the past 5 years, the average Total Assets Growth Rate was 88.40% per year.

During the past 7 years, Recursion Pharmaceuticals's highest 3-Year average Total Assets Growth Rate was 108.80%. The lowest was 68.70%. And the median was 81.00%.

Total Assets is connected with ROA %. Recursion Pharmaceuticals's annualized ROA % for the quarter that ended in Mar. 2026 was -33.41%. Total Assets is also linked to Revenue through Asset Turnover. Recursion Pharmaceuticals's Asset Turnover for the quarter that ended in Mar. 2026 was 0.00.

Recursion Pharmaceuticals  (NAS:RXRX) Total Assets Explanation

Total Assets is connected with ROA %.

Recursion Pharmaceuticals's annualized ROA % for the quarter that ended in Mar. 2026 is

ROA %=Net Income (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=-470.016/( (1474.13+1339.522)/ 2 )
=-470.016/1406.826
=-33.41 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Recursion Pharmaceuticals's Asset Turnover for the quarter that ended in Mar. 2026 is

Asset Turnover
=Revenue (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=6.301/( (1474.13+1339.522)/ 2 )
=6.301/1406.826
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Recursion Pharmaceuticals Total Assets Related Terms

Recursion Pharmaceuticals Total Assets Historical Data

* Premium members only.

The historical data trend for Recursion Pharmaceuticals's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Recursion Pharmaceuticals Total Assets Chart

Recursion Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Assets
Get a 7-Day Free Trial 610.35 701.29 653.70 1,448.60 1,474.13

Recursion Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,305.23 1,302.36 1,399.53 1,474.13 1,339.52
RXRX
77GF Score
Recursion Pharmaceuticals Inc RXRX
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Recursion Pharmaceuticals Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Recursion Pharmaceuticals's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (A: Dec. 2025 )+Total Liabilities (A: Dec. 2025 )
=1130.865+343.265
=1,474.13

Recursion Pharmaceuticals's Total Assets for the quarter that ended in Mar. 2026 is calculated as

Total Assets=Total Equity (Q: Mar. 2026 )+Total Liabilities (Q: Mar. 2026 )
=1024.769+314.753
=1,339.52

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of $1,339.52 Mil mean?
Recursion Pharmaceuticals (RXRX) has a Total Assets of $1,339.52 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Recursion Pharmaceuticals and its competitors.
Is Recursion Pharmaceuticals' Total Assets too high?
Recursion Pharmaceuticals' current Total Assets is $1,339.52 Mil. Overall, Recursion Pharmaceuticals has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Recursion Pharmaceuticals' Total Assets compare to ABSI and GLUE?
Recursion Pharmaceuticals' Total Assets of $1,339.52 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Recursion Pharmaceuticals and its competitors. Recursion Pharmaceuticals's current Total Assets is $1,339.52 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Recursion Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Recursion Pharmaceuticals (RXRX) is currently considered Fairly Valued. The stock's GF Value™ is $4.14, compared to a current price of $3.96 — trading 4.3% below its estimated fair value. The current Total Assets is $1,339.52 Mil. Recursion Pharmaceuticals' overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Recursion Pharmaceuticals (RXRX), the current Total Assets is $1,339.52 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Recursion Pharmaceuticals (RXRX) Overvalued in 2026?

Based on GuruFocus' analysis, Recursion Pharmaceuticals stock appears to be undervalued. The current stock price of $3.96 is trading 4.3% below its estimated GF Value™ of $4.14. GuruFocus considers Recursion Pharmaceuticals to be Fairly Valued.

Key valuation signals for RXRX:

  • Total Assets: $1,339.52 Mil
  • GF Value™: $4.14 vs. price of $3.96 (4.3% below fair value)
  • GF Score™: 77/100 with 4 warning signs

No single metric tells the full story. See the RXRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Recursion Pharmaceuticals Business Description

Other Exchanges RXRX:Mexico
Address 41 South Rio Grande Street, Salt Lake City, UT, USA, 84101
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.
77GF Score

Get the complete analysis for RXRX

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.96
Price
$4.14
GF Value